Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced management's participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 12:35 p.m. ET. A live webcast will be available on their website, with a replay accessible for 90 days afterward.

Specializing in antiviral therapeutics, Atea focuses on developing treatments for severe viral infections, including COVID-19, hepatitis C, dengue, and RSV, leveraging their proprietary nucleotide and nucleoside prodrug platform.

BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced that management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 12:35 p.m. ET.

A live webcast of the presentation will be available on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide and nucleoside prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally- available, potent, and selective purine nucleotide and nucleoside prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus (HCV) infection, dengue virus, and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Investors:
Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com

Media:
Carol Guaccero
301-606-4722
contactus@ateapharma.com

FAQ

When is Atea Pharmaceuticals' presentation at the Evercore ISI HealthCONx Conference?

Atea Pharmaceuticals will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 12:35 p.m. ET.

How can I watch the Atea Pharmaceuticals conference presentation?

The Atea Pharmaceuticals conference presentation will be available via live webcast on their website.

What is the focus of Atea Pharmaceuticals?

Atea Pharmaceuticals focuses on discovering and developing antiviral therapeutics for life-threatening viral infections.

What viruses is Atea Pharmaceuticals targeting with their treatments?

Atea targets several viruses, including SARS-CoV-2 (COVID-19), hepatitis C, dengue, and respiratory syncytial virus (RSV).